Sanofi · 1 day ago
Scientist, Retinal Degeneration
Cambridge, MA
Full-time
Onsite
Mid, Senior Level
$86K/yr - $124K/yr
3+ years expSanofi is a biopharmaceutical company focused on improving lives through innovative research. They are seeking a highly motivated Scientist to conduct preclinical drug discovery research for retinal diseases, driving breakthroughs in ophthalmology therapeutics.
Health CareLife SciencePharmaceuticalTherapeutics
Responsibilities
Design, execute, and document research studies to validate therapeutic targets and discover preclinical drug candidates
Develop and optimize molecular, biochemical, and cellular assays to assess disease processes, target activity, and biomarkers in models of retinal disease and degeneration
Perform experiments using genetic, biologic, and small molecule perturbations to validate targets, evaluate therapeutic strategies, and assess the pharmacology and efficacy preclinical candidates
Analyze and interpret experimental data to support target prioritization, preclinical candidate selection, and go/no-go decisions
Actively contribute to interdisciplinary research projects in a highly collaborative and matrixed manner
Prepare high-quality presentations and documentation to support project deliverables, publications, patent filings, and regulatory filings
Effectively communicate findings internally and externally through presentation and publication
Qualification
Required
Earned Bachelor's degree in biological sciences, bioengineering or other relevant field and 6+ years of research experience in an academic or biopharmaceutical setting OR earned Master's degree in biological sciences, bioengineering or other relevant field and 3+ years research experience in an academic or biopharmaceutical setting
Solid understanding of degenerative disease mechanisms required, with experience in retinal disease and degeneration or neurodegeneration research strongly preferred
Experience in drug development required, preferably within the biopharmaceutical industry
Experience with a broad range of molecular, cellular, and biochemical methods and assay development
Extensive cell culture experience, including work with primary cells, iPSC-derived cells, or 3D in vitro models
Experience designing, executing, and interpreting in vitro experiments using genetic or pharmacologic approaches to assess gene and protein function, signaling pathway activity, and/or cellular processes
Demonstrated ability to prepare high-quality documents including experimental protocols, SOPs, technical reports, and presentations
Track record of impactful contributions to research projects and scientific publications
Preferred
Experience using computational tools (e.g., R, Python) to analyze data strongly preferred
Experience evaluating target engagement and efficacy of preclinical candidates
Experience developing high-throughput assays and using automated screening platforms and robotics
Experience with live-cell and high-content imaging and analyses
Experience authoring regulatory documents to support IND or CTA submissions
Benefits
High-quality healthcare
Prevention and wellness programs
At least 14 weeks’ gender-neutral parental leave
Company
Sanofi
Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.
10001+ employees
H1B Sponsorship
Sanofi has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (101)
2024 (68)
2023 (59)
2022 (78)
2021 (38)
2020 (38)
Funding
Current Stage
Public CompanyTotal Funding
$6.97BKey Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B
Leadership Team
Paul Hudson
Chief Executive Officer
Francois-Xavier Roger
Chief Financial Officer
Recent News
2026-01-08
Company data provided by crunchbase